Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Clascoterone is an androgen receptor antagonist used for the topical treatment of acne vulgaris in patients 12 years of age and older. Clascoterone (cortexolone 17α-propionate, CB-03-01) is a novel antagonist of androgen receptors.
- Mechanism
- Curator reviewed · 5 references
Acne is a multifactorial skin condition characterized by excess sebum production, epithelial hyperkeratinization, proliferation of the skin commensal bacteria, and inflammation. Circulating and locally synthesized natural ligands, testosterone and dihydrotestosterone (DHT), serve as causative factors in both males and females. Upon binding of DHT, the DHT-androgen receptor complex dimerizes and translocates to the nucleus where it promotes the transcription of genes involved in acne pathogenesis, including proliferation and differentiation of sebocytes, excess sebum production, and inflammatory cytokine production. Clascoterone is a potent antagonist at ARs and competes for androgens in binding to the receptor, thereby inhibiting downstream signalling of ARs that promote acne.
Androgenetic alopecia is also an androgen-dependent and highly genetic condition. Dihydrotestosterone (DHT) binds to ARs expressed on dermal papilla cells (DPC) in the scalp to induce AR-mediated transcription of genes that contribute to androgenic alopecia. By blocking the interaction between DHT and aARs, clascoterone inhibits AR-regulated transcription and DHT-induced IL-6 synthesis.
- Primary indication
- Clascoterone is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.Curator reviewed · 1 structured indication
- Formula / weight
- C24H34O5 · 402.531 g/mol (avg)
- First approval
- Canada, 2023 · United States, 2021 · European Union, 2026
- Also known as
- Cortexolone 17alpha-propionate
- Code names
- CB-03-01
- Brand names
- Winlevi
Resolves to
GPNHMOZDMYNCPO-PDUMRIMRSA-NSMILES[H][C@@]12CC[C@](OC(=O)CC)(C(=O)CO)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12CWhat you can answer from here — as of June 27, 2023
Which drugs share a target with Clascoterone, and which of those have an active Phase 3 trial?